Immune thrombocytopenia (ITP) is a reason of thrombocytopenia that is characterized by isolated thrombocytopenia in childhood. Epstein barr virus infection (EBV) is a mildly and uncomplicated ailment that might be a trigger factor for ITP. Here, we discuss two cases with ITP secondary Epstein barr virus infection.
11 September 2026 in Anatolian Current Medical Journal
Aims: This study aims to evaluate the relationship between asthma self-efficacy levels and asthma control in adolescents aged 12-18 with physician-diagnosed asthma. Additionally, factors associated with asthma control status were examined.Methods: In this cross-sectional analytical study, 108 adolescents aged 12-18 years with at least one year of physician-diagnosed asthma were included. Data were collected using a sociodemographic and clinical information form, the Asthma Control Test (ACT), and the Adolescent Asthma Self-Efficacy Questionnaire (AASEQ). Those with an ACT score of 19 or lower were classified as not having well-controlled asthma, while those with an ACT score of 20 or higher were classified as having well-controlled asthma. Descriptive statistics, group comparisons, correlation analysis, and simple linear regression analysis were used for data analysis. A p-value of
23 October 2026 in Annals of Allergy, Asthma & Immunology
Survival in high-risk neuroblastoma has improved with multimodal treatment approaches and numerous studies have focused on treatment-related side effects. This study examines the prevalence, severity and risks of late effects following high-dose chemotherapy and autologous stem cell transplantation in high risk neuroblastoma patients. This study included high-risk neuroblastoma patients who underwent autologous stem cell transplantation and survived 5 years without relapse in a single center. Of the 41 patients who received high-dose chemotherapy and autologous stem cell transplantation, 20 patients survived without relapse for at least 5 years and were included in the analysis. Amid 20 patients, 12 patients (60%) were men. The median age of the patients was 13.5 years at the last follow up. After six cycles of induction chemotherapy, 11 patients (55%) received busulfan–melphalan as the consolidation regimen, while 9 patients (45%) received carboplatin–etoposide–melphalan. The median follow-up after transplantation was 9 years. At least one complication occurred in 19 out of 20 patients (95%). Severe late complications were observed in seven patients. Two patients developed treatment-related secondary neoplasms. In contrast to the literature, the most common adverse event was focal nodular hyperplasia (40%) in the liver. The second most common adverse event was ovarian failure (37.5%) and the third most common was hearing loss (35%). Endocrine pathologies were more common in patients receiving busulfan–melphalan as the consolidation regimen. This study highlights the future risks of side effects in high-risk neuroblastoma survivors and emphasizes the need for a long-term follow-up.